Takeda acquires Cour celiac disease treatment for up to $420 million
The Japanese company has bought the exclusive global license to an immune modifying nanoparticle designed to induce tolerance to gluten in patients with celiac disease.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Celiac Disease | Coeliac Disease | Gluten | Japan Health | Nanotechnology | Pharmaceuticals